← Back to Press PAGE

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Rosalind Study

Cure51

Science

Patients

Publication Date:

Mar 3, 2026

How does AI help advance our Rosalind Study? Our CEO Nicolas Wolikow breaks it down in an interview with FW.MEDIA.

Credit: FW.MEDIA

Nicolas Wolikow, CEO

Updated: April 1, 2026

Table of Contents

NEWS

THEY SPREAD THE WORD

Go to Press page

Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

The Rosalind Study | Decoding Exceptional Cancer Survival Across GBM, ES-SCLC and mPDAC

The Rosalind Study | Three cohorts, one mission: decoding exceptional Cancer survival across GBM, ES-SCLC and mPDAC

cure51-techbio-biotech-oncology-data-company-ai

cure51-techbio-biotech-oncology-data-company-ai

TechBio vs. Biotech: Why Cure51 is a TechBio Company

Apr 14, 2026

READ MORE

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Contact us